Clinical trial: The effects of a fermented milk containing three probiotic bacteria in patients with irritable bowel syndrome - A randomized, double-blind, controlled study

Alimentary Pharmacology and Therapeutics

Volumn 31, Issue 2, 2010, Pages 218-227

  Simren M ^a   Ohman L ^a   Olsson, J ^b   Svensson, U ^c   Ohlson, K ^c   Posserud, I ^a   Strid, H ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b KPL Good Food Practice AB   (Sweden)

^c Arla Foods   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

PROBIOTIC AGENT; YOGHURT;

ADULT; AGED; ARTICLE; BIFIDOBACTERIUM ANIMALIS; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DISTRESS SYNDROME; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FERMENTED PRODUCT; GASTROINTESTINAL SYMPTOM; HUMAN; IRRITABLE COLON; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS PARACASEI; MAJOR CLINICAL STUDY; MALE; MILK; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANIMALS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTESTINAL MUCOSA; IRRITABLE BOWEL SYNDROME; LACTOBACILLUS ACIDOPHILUS; MALE; MIDDLE AGED; MILK; PATIENT COMPLIANCE; PROBIOTICS; QUALITY OF LIFE; QUESTIONNAIRES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 72949103471     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2009.04183.x     Document Type: Article

References (43)

1. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006 130 : 1480 1491.
2. Spiller R, Aziz Q, Creed F, et al. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut 2007 56 : 1770 1798.
3. Posserud I, Ersryd A, Simren M. Functional findings in irritable bowel syndrome. World J Gastroenterol 2006 12 : 2830 2838.
4. Ohman L, Simren M. New insights into the pathogenesis and pathophysiology of irritable bowel syndrome. Dig Liver Dis 2007 39 : 201 215.
5. King TS, Elia M, Hunter JO. Abnormal colonic fermentation in irritable bowel syndrome. Lancet 1998 352 : 1187 1189.
6. Posserud I, Stotzer PO, Bjornsson ES, Abrahamsson H, Simren M. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut 2007 56 : 802 808. (Pubitemid 46854194)
7. Nobaek S, Johansson ML, Molin G, Ahrne S, Jeppsson B. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol 2000 95 : 1231 1238.
8. O'Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005 128 : 541 551.
9. Kim HJ, Camilleri M, McKinzie S, et al. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2003 17 : 895 904.
10. O'Sullivan MA, O'Morain CA. Bacterial supplementation in the irritable bowel syndrome. A randomised double-blind placebo-controlled crossover study. Dig Liver Dis 2000 32 : 294 301.
11. Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Muller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut 1999 45 (Suppl 2 II43 7.
12. O'Donnell LJ, Virjee J, Heaton KW. Detection of pseudodiarrhoea by simple clinical assessment of intestinal transit rate. BMJ 1990 300 : 439 440.
13. Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther 1997 11 : 395 402.
14. Mangel AW, Hahn BA, Heath AT, et al. Adequate relief as an endpoint in clinical trials in irritable bowel syndrome. J Int Med Res 1998 26 : 76 81.
15. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983 67 : 361 370.
16. Herrmann C. International experiences with the Hospital Anxiety and Depression Scale - a review of validation data and clinical results. J Psychosom Res 1997 42 : 17 41.
17. Hahn BA, Kirchdoerfer LJ, Fullerton S, Mayer E. Evaluation of a new quality of life questionnaire for patients with irritable bowel syndrome. Aliment Pharmacol Ther 1997 11 : 547 552.
18. Hahn BA, Kirchdoerfer LJ, Fullerton S, Mayer E. Patient-perceived severity of irritable bowel syndrome in relation to symptoms, health resource utilization and quality of life. Aliment Pharmacol Ther 1997 11 : 553 559.
19. Watson ME, Lacey L, Kong S, et al. Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2001 96 : 455 459.
20. Kajander K, Hatakka K, Poussa T, Farkkila M, Korpela R. A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. Aliment Pharmacol Ther 2005 22 : 387 394.
21. Kassinen A, Krogius-Kurikka L, Makivuokko H, et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 2007 133 : 24 33.
22. Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000 95 : 3503 3506.
23. Maxwell PR, Rink E, Kumar D, Mendall MA. Antibiotics increase functional abdominal symptoms. Am J Gastroenterol 2002 97 : 104 108.
24. Di Stefano M, Strocchi A, Malservisi S, Veneto G, Ferrieri A, Corazza GR. Non-absorbable antibiotics for managing intestinal gas production and gas-related symptoms. Aliment Pharmacol Ther 2000 14 : 1001 1008.
25. Pimentel M, Park S, Mirocha J, Kane SV, Kong Y. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med 2006 145 : 557 563.
26. Yang J, Lee HR, Low K, Chatterjee S, Pimentel M. Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS. Dig Dis Sci 2008 53 : 169 174.
27. Agrawal A, Houghton LA, Morris J, et al. Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173-010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2009 29 : 104 114.
28. Guyonnet D, Chassany O, Ducrotte P, et al. Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. Aliment Pharmacol Ther 2007 26 : 475 486.
29. Whorwell PJ, Altringer L, Morel J, et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 2006 101 : 1581 1590.
30. Niv E, Naftali T, Hallak R, Vaisman N. The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome - a double blind, placebo-controlled, randomized study. Clin Nutr 2005 24 : 925 931.
31. Moayyedi P, Ford AC, Talley NJ, et al. The efficacy of probiotics in the therapy of irritable bowel syndrome: a systematic review. Gut 2008 [Epub ahead of print].
32. Crittenden R, Saarela M, Mättö J, et al. Lactobacillus paracasei subsp. paracasei F19: Survival, ecology and safety in the human intestinal tract - a survey of fedding studies within the PROBDEMO project. Microb. Ecol. Health Dis. 2002 14 (Suppl 3 22 6.
33. Ljungh Å, Lan J, Yanagizawa N. Isolation, selection and characteristics of lactobacillus paracasei subsp. paracasei F19. Microb. Ecol. Health Dis. 2002 14 (Suppl 3 4 6.
34. Sullivan Å, Bennet R, Viitanen M, Palmgren AC, Nord CE. Influence of lactobacillus F19 on intestinal microflora in children and elderly persons and impact on helicobacter pylori infections. Microb. Ecol. Health Dis. 2002 14 (Suppl 3 17 21.
35. Ohlson K, Björneholm S, Fondén R, Svensson U. Lactobacillus F19 - a probiotic strain suitable for consumer products. Microb. Ecol. Health Dis. 2002 14 (Suppl 3 27 32.
36. Sullivan A, Barkholt L, Nord CE. Lactobacillus acidophilus, Bifidobacterium lactis and Lactobacillus F19 prevent antibiotic-associated ecological disturbances of Bacteroides fragilis in the intestine. J Antimicrob Chemother 2003 52 : 308 311.
37. Drouault-Holowacz S, Bieuvelet S, Burckel A, Cazaubiel M, Dray X, Marteau P. A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome. Gastroenterol Clin Biol 2008 32 : 147 152.
38. Sinn DH, Song JH, Kim HJ, et al. Therapeutic effect of Lactobacillus acidophilus-SDC 2012, 2013 in patients with irritable bowel syndrome. Dig Dis Sci 2008 53 : 2714 2718.
39. Williams E, Stimpson J, Wang D, et al. Clinical trial: a multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study. Aliment Pharmacol Ther 2009 29 : 97 103.
40. Camilleri M, Northcutt AR, Kong S, Dukes GE, McSorley D, Mangel AW. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet 2000 355 : 1035 1040.
41. Muller-Lissner SA, Fumagalli I, Bardhan KD, et al. Tegaserod, a 5-HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001 15 : 1655 1666.
42. McFarland LV, Dublin S. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J Gastroenterol 2008 14 : 2650 2661.
43. Mountzouris KC, McCartney AL, Gibson GR. Intestinal microflora of human infants and current trends for its nutritional modulation. Br J Nutr 2002 87 : 405 420.